Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation

Pharmaceuticals

Amy H. Moore¹  Matthew J. Bigbee²  Grace E. Boynton²  Colin M. Wakeham²  Hilary M. Rosenheim²  Christopher J. Staral²  James L. Morrissey² 

[1] id="af1-pharmaceuticals-03-01812">Department of Biology, Carleton College, one north college street, Northfield, MN 55057, U

关键词: Non-steroidal anti-inflammatory drugs;    Alzheimer's disease;    Parkinson's disease;    cyclooxygenase;    neuroinflammation;   

DOI  :  10.3390/ph3061812

来源: mdpi

【 摘 要 】

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases with age as the greatest risk factor. As the general population experiences extended life span, preparation for the prevention and treatment of these and other age-associated neurological diseases are warranted. Since epidemiological studies suggested that non-steroidal anti-inflammatory drug (NSAID) use decreased risk for AD and PD, increasing attention has been devoted to understanding the costs and benefits of the innate neuroinflammatory response to functional recovery following pathology onset. This review will provide a general overview on the role of neuroinflammation in these neurodegenerative diseases and an update on NSAID treatment in recent experimental animal models, epidemiological analyses, and clinical trials.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.